Pacchiana, C.M.

patient eptifibatide state trial infarction pursuit revascularization study treatment effect 30 days treatment death placebo 0.001 non-us patients eptifibatide therapy therapy point non-u /iiia syndrome effect event end point ischemic group infusion platelet reduction glycoprotein benefit study drug infusion patients randomized percutaneou randomized incidence outcome strategy range country investigator high-dose eptifibatide study drug circulation population management heparin 96 hours angina procedure hospital difference world ischemic syndromes figure non-us sites receptor suppression pursuit trial table receptor st-segment elevation variability 100 patients integrilin therapy elevation ischemic events 0.0001 blood high-dose integrilin randomization history efficacy st-segment gusto surgery inhibition practice lincoff michael lincoff